Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Volume Increase – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw unusually-high trading volume on Tuesday . Approximately 7,101 shares changed hands during mid-day trading, an increase of 92% from the previous session’s volume of 3,696 shares.The stock last traded at $44.03 and had previously closed at $49.75.

Analyst Ratings Changes

ZLDPF has been the subject of several recent analyst reports. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday. Finally, BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Zealand Pharma A/S presently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of 3.14 and a beta of 0.86. The stock has a fifty day moving average of $47.99 and a 200 day moving average of $59.11.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.50. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%.The firm had revenue of $5.33 million during the quarter, compared to the consensus estimate of $2.81 million. On average, analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.